Table 1.
Baseline cohort characteristics
| LPLD (44 patients) | HPSD (44 patients) | P | |
|---|---|---|---|
| Age (mean, SD) | 59.7 ± 10.0 | 62.9 ± 8.2 | 0.11 |
| Females (n, %) | 14 (31.8%) | 13 (29.5%) | 0.50 |
| PAF (n, %) | 21 (47.7%) | 15 (34.1%) | 0.42 |
| CHADSVASc score | 1.5 ± 1.5 | 2 ± 2 | 0.44 |
| BMI (kg/m2) | 29.2 ± 4.8 | 29.2 ± 5.6 | 0.66 |
| Hypertension (n, %) | 14 (31.8%) | 25 (56.8%) | 0.02 |
| IHD (n, %) | 7 (15.9%) | 5 (11.4%) | 0.38 |
| Stroke (n, %) | 2 (4.5%) | 1 (2.3%) | 0.50 |
| Congestive cardiac failure (n, %) | 12 (27.3%) | 11 (25%) | 0.50 |
| Diabetes mellitus (n, %) | 2 (4.5%) | 3 (6.8%) | 0.48 |
| OSA (n, %) | 2 (4.5%) | 7 (15.9%) | 0.08 |
| LAVI (mL/m3) | 40.0 ± 11.2 | 43.0 ± 21.2 | 0.31 |
| LVEDD (mm) | 51.3 ± 6.5 | 50.4 ± 6.7 | 0.56 |
| LVESD (mm) | 35.8 ± 8.8 | 34.9 ± 8.9 | 0.71 |
| LVEF (%) | 54.6 ± 11.4 | 55.4 ± 13.0 | 0.79 |
| E/e′ ratio | 9.8 ± 4.2 | 9.4 ± 2.9 | 0.57 |
| RVSP (mmHg) | 27.9 ± 7.4 | 28.5 ± 9.7 | 0.82 |
| Anticoagulation pre ablation (n, %) | 37 (84.1%) | 41 (93.2%) | 0.09 |
| Antiplatelet use (n, %) | 5 (11.4%) | 2 (4.5%) | 0.22 |
| ACE/ARB use (n, %) | 16 (36.4%) | 22 (50%) | 0.14 |
| Mineralcorticoid use (n, %) | 3 (7.8%) | 6 (13.6%) | 0.24 |
| Anti-arrhythmic drug use (n, %) | 35 (79.5%) | 35 (79.5%) | 1.00 |
| Flecainide | 9 (20.5%) | 13 (6.8%) | 0.46 |
| Sotalol | 15 (34.1%) | 15 (34.1%) | 1.00 |
| Amiodarone | 10 (22.7%) | 8 (18.2%) | 0.79 |
| Rhythm monitoring (n, %) | 0.94 | ||
|
38 (86.4%) | 39 (88.6%) | |
|
5 (11.3%) | 4 (9.1%) |
Bold indicates P < 0.05.
ACE-I, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; BMI, body mass index; HPSD, higher power short duration; IHD, ischaemic heart disease; LAVI, left atrial indexed volume; LPLD, lower power longer duration; LVEDD, left ventricular end diastolic diameter; LVESD, left ventricular end systolic diameter; LVEF, left ventricular ejection fraction; OSA, obstructive sleep apnoea; PAF, paroxysmal AF; RVSP, right ventricular systolic pressure.